Menu
Home
About Us
Company Overview
Board and Management
Corporate Governance
Products
Our Products
Vigo Heart
Vigo Vitals (Available soon)
In-Hospital Monitoring
Remote Monitoring
References
Clinical Papers and Studies
Investors
Investor Welcome
Corporate Details
Latest News
ASX Announcements Archive (QRX)
Contact
Enquire Now
Email Alerts
Home
About Us
Products
Investors
Contact
Menu Section Title
Menu Section List
Home
>
Investors
>
ASX Announcements Archive (QRX)
Investor Welcome
Corporate Details
Latest News
ASX Announcements Archive (QRX)
ASX Announcements Archive (QRX)
23-May-2018
Removal from Official List
20-Apr-2018
Appendix 4C - Quarter Ended 31 March 2018
27-Mar-2018
Initial Director's Interest Notice
23-Mar-2018
Director Appointment
26-Feb-2018
Half Yearly Report and Accounts - 31 December 2017
18-Jan-2018
Appendix 4C - Quarter Ended 31 December 2017
20-Nov-2017
Results of Meeting
20-Nov-2017
Chairman's Address to Shareholders
18-Oct-2017
Notice of Annual General Meeting/Proxy Form
17-Oct-2017
Appendix 4C - Quarter Ended 30 September 2017
28-Sep-2017
Appendix 4G - Corporate Governance
28-Sep-2017
Annual Report to shareholders
30-Aug-2017
Preliminary Final Report
31-Jul-2017
Appendix 4C - Quarter Ended 30 June 2017
11-Apr-2017
Appendix 4C - Quarter Ended 31 March 2017
22-Feb-2017
Half Yearly Report and Accounts - 31 December 2016
17-Jan-2017
Appendix 4C - Quarter Ended 31 December 2016
19-Dec-2016
Auditor Appointment / Resignation
29-Nov-2016
Results of Meeting
29-Nov-2016
Chairman's Address to Shareholders
25-Oct-2016
Notice of Annual General Meeting/Proxy Form
19-Oct-2016
Appendix 4C - Quarter Ended 30 September 2016
14-Oct-2016
Initial Director's Interest Notice- J Rainbow
14-Oct-2016
Initial Director's Interest Notice- T Heesh
14-Oct-2016
Final Director's Interest Notice- B Hancox
14-Oct-2016
Final Director's Interest Notice- R Treagus
11-Oct-2016
Change in Board Composition
22-Aug-2016
Change of Registered Office & Company Secretary
18-Aug-2016
Appendix 4G - Corporate Governance Statement
18-Aug-2016
Preliminary Final Report - 30 June 2016
5-Aug-2016
Appendix 4C - Quarter Ended 30 June 2016
27-May-2016
Response to ASX Query
26-May-2016
Change of Director's Interest Notice - Bruce Hancox
19-May-2016
Results of 2015 Annual General Meeting
19-May-2016
Chairman's Address to Shareholders
10-May-2016
Appendix 4C - Quarter Ended 31 March 2016
15-Apr-2016
Notice of 2015 Annual General Meeting/Proxy Form
11-Mar-2016
Half Yearly Report and Accounts - 31 December 2015
9-Feb-2016
Appendix 4C - Quarter Ended 31 December 2015
9-Feb-2016
Appendix 4C - Quarter Ended 30 September 2015
9-Feb-2016
Appendix 4G - Corporate Governance Statement
9-Feb-2016
Annual report and full year financial results - 30 June 2015
9-Feb-2016
Appendix 4C - Quarter Ended 30 June 2015
24-Dec-2015
Letter to Shareholders
9-Dec-2015
Letter to Shareholders
7-Dec-2015
Letter to Shareholders
11-Nov-2015
Letter to Shareholders /Notice of meeting of Creditors
26-Oct-2015
Letter to Shareholders
2-Oct-2015
Letter to Shareholders
15-Sep-2015
ASX Announcement
7-Sep-2015
Letter to Shareholders
24-Jun-2015
Letter to Shareholders
22-Jun-2015
ASX Announcement
27-May-2015
Response to ASX Price Query
22-May-2015
Appointment of Voluntary Administrator
22-May-2015
Suspension from Official Quotation
22-Apr-2015
Appendix 4C - Quarter Ended 31 March 2015
2-Apr-2015
Response to ASX Price Query
10-Mar-2015
Change in substantial holding
25-Feb-2015
Half Yearly Report and Accounts - 31 December 2014
27-Jan-2015
Appendix 4C - Quarter Ended 31 December 2014
29-Oct-2014
Results of 2014 Annual General Meeting
29-Oct-2014
Chairman's Address to Shareholders
24-Oct-2014
Appendix 4C - Quarter Ended 30 September 2014
26-Sep-2014
Annual Report to Shareholders - 2014
26-Sep-2014
Notice of 2014 Annual General Meeting and Proxy Form
28-Aug-2014
2014 Annual General Meeting - Wednesday, 29 October 2014
27-Aug-2014
Preliminary Final Report - 30 June 2014
14-Aug-2014
QRxPharma Halts Moxduo Development
31-Jul-2014
QRxPharma General Shareholder Update
17-Jul-2014
Appendix 4C - Quarter Ended 30 June 2014
14-Jul-2014
Initial Director's Interest Notice - Richard Treagus
14-Jul-2014
Initial Director's Interest Notice - Bruce Hancox
14-Jul-2014
Final Director's Interest Notice - Peter Campbell
14-Jul-2014
Final Director's Interest Notice - Michael Quinn
14-Jul-2014
Final Director's Interest Notice - Gary Pace
14-Jul-2014
Final Director's Interest Notice - Peter Farrell
11-Jul-2014
Feedback on End-of-Review Meeting with the FDA on Moxduo
9-Jul-2014
Results of 9 July 2014 General Meeting
9-Jul-2014
Board Resignations and General Meeting Chairman's Address
27-Jun-2014
Letter to Shareholders from Chairman of General Meeting
26-Jun-2014
Change of Director's Interest Notice - Michael Quinn
4-Jun-2014
FDA Confirms Review Meeting Regarding MOXDUO NDA
3-Jun-2014
Notice of General Meeting/Proxy Form - 9 July 2014
29-May-2014
Change of Director's Interest Notice - Peter Campbell
29-May-2014
Change of Director's Interest Notice - Michael Quinn
29-May-2014
Change of Director's Interest Notice - Peter Farrell
26-May-2014
Complete Response Letter from FDA regarding Moxduo NDA
19-May-2014
Moxduo Status Overview May 2014
14-May-2014
Notice under Sections 249D & 203D of the Corporations Act
7-May-2014
Final Director's Interest Notice - John Holaday
7-May-2014
Change of Director's Interest Notice - Gary Pace
7-May-2014
Change of Director's Interest Notice - John Holaday
2-May-2014
Appendix 3B - Option Issue
2-May-2014
CEO Remuneration Package and Key Terms
2-May-2014
Reissue - Dr. Edward Rudnic Appointed CEO of QRxPharma
2-May-2014
Dr. Edward Rudnic Appointed CEO of QRxPharma
29-Apr-2014
Appendix 4C - Quarter Ended 31 March 2014
23-Apr-2014
CEO Discusses Moxduo Advisory Committee Meeting Outcomee
23-Apr-2014
QRxPharma Issues Statement On Moxduo Advisory Committee
22-Apr-2014
FDA Webcast Details For Moxduo Advisory Committee Meeting
17-Apr-2014
Moxduo Post Advisory Committee Meeting Investor Call Details
17-Apr-2014
Trading Halt
24-Mar-2014
FDA sets 22 April 2014 for Moxduo Advisory Committee Meeting
10-Mar-2014
Appendix 3B - Exercise of Stock Options
25-Feb-2014
ASX / Media Release - Results Half Year 31 December 2013
25-Feb-2014
Half Yearly Report and Accounts - 31 December 2013
30-Jan-2014
Appendix 3B - Exercise of Stock Options
29-Jan-2014
Appendix 4C - Quarter Ended 31 December 2013
22-Jan-2014
Details of Company Address
17-Dec-2013
Holaday - Cease to be substantial holder
17-Dec-2013
Change of Director's Interest Notice - Peter Campbell
16-Dec-2013
QRxPharma Despatches SPP Holding Statements
13-Dec-2013
Appendix 3B - Share Purchase Plan
13-Dec-2013
$4.1 Million SPP Completes A$11.6 Million Capital Raising
11-Dec-2013
25 May 2014 as New PDUFA Date for MOXDUO NDA
27-Nov-2013
MOXDUO License with TEVA for Commercialisation in Israel
26-Nov-2013
QRxPharma Refiles MOXDUO New Drug Application with the FDA
19-Nov-2013
Change in substantial holding
19-Nov-2013
Appendix 3B - Option Issue
18-Nov-2013
Notification Section 708A(5)(e) Corporations Act 2001 (Cth)
18-Nov-2013
Appendix 3B - Placement Issue announced 13 November 2013
15-Nov-2013
Share Purchase Plan Opens 19 November 2013
13-Nov-2013
Placement and SPP - ASX Listing Rule 3.10.3 Notice
13-Nov-2013
Results of 2013 Annual General Meeting
13-Nov-2013
Chairman and Managing Director Addresses to Shareholders
13-Nov-2013
Successful Completion of A$7.5 Million Placement
11-Nov-2013
Investor Update and Capital Raising - November 2013
11-Nov-2013
Trading Halt
28-Oct-2013
Appendix 4C - Quarter Ended 30 September 2013
15-Oct-2013
QRxPharma Extends MOXDUO License with Aspen
10-Oct-2013
Notice of 2013 Annual General Meeting and Proxy Form
9-Oct-2013
QRxPharma reports Positive Meeting with the FDA on MOXDUO
25-Sep-2013
Annual Report to Shareholders - 2013
17-Sep-2013
2013 Annual General Meeting - Wednesday, 13 November 2013
11-Sep-2013
QRxPharma Announces MOXDUO License with Aspen
6-Sep-2013
FDA Schedules Review Meeting Regarding MOXDUO NDA
29-Aug-2013
ASX/ Media Release - Preliminary Final Report 30 June 2013
29-Aug-2013
Preliminary Final Report - 30 June 2013
28-Aug-2013
CEO discusses Complete Response Letter on Open Briefing
28-Aug-2013
Complete Response Letter from FDA regarding MOXDUO NDA
26-Aug-2013
Trading Halt
26-Jul-2013
Appendix 4C - Quarter Ended 30 June 2013
22-Jul-2013
QRxPharma Announces Collaboration with Aesica
9-Jul-2013
Change in substantial holding
27-Jun-2013
CEO discusses MOXDUO NDA Review Update on Open Briefing
26-Jun-2013
QRxPharma Updates MOXDUO NDA Review
26-Jun-2013
Trading Halt
14-Jun-2013
Appendix 3B - Exercise of Stock Options
12-Jun-2013
QRxPharma Granted US Patent on Hybrid Opioids
5-Jun-2013
Appendix 3B - Exercise of Stock Options
17-May-2013
FDA sets 17 July 2013 for MOXDUO Advisory Committee Meeting
9-May-2013
Appendix 3B - Exercise of Stock Options
29-Apr-2013
Appendix 4C - Quarter Ended 31 March 2013
14-Mar-2013
FDA sets 26 August 2013 as new PDUFA date for MOXDUO NDA
1-Mar-2013
Investor Presentation Update - March 2013
28-Feb-2013
QRxPharma Resubmits MOXDUO New Drug Application to the FDA
21-Feb-2013
Appendix 3B - Option Issue
18-Feb-2013
Investor Presentation Update - February 2013
18-Feb-2013
Half Yearly Report and Accounts - 31 December 2012
24-Jan-2013
Appendix 4C - Quarter Ended 31 December 2012
17-Jan-2013
CEO discusses Path Forward for Resubmission of MOXDUO NDA
16-Jan-2013
Path Forward For Resubmission of MOXDUO NDA
14-Jan-2013
Appendix 3B - Exercise of Stock Options
20-Dec-2012
Appendix 3B - Exercise of Stock Options
11-Dec-2012
Investor Presentation Update - December 2012
6-Dec-2012
Change in substantial holding
6-Dec-2012
MAP Cancellation
6-Dec-2012
Change in substantial holding
28-Nov-2012
Ceasing to be a substantial holder
22-Nov-2012
Change of Director's Interest Notice - Michael Quinn
22-Nov-2012
Change of Director's Interest Notice - Gary Pace
22-Nov-2012
Change of Director's Interest Notice - Peter Farrell
21-Nov-2012
Change of Director's Interest Notice - Michael Quinn
12-Nov-2012
Change of Director's Interest Notice - John Holaday
12-Nov-2012
Appendix 3B - Option Issue
12-Nov-2012
Change of Director's Interest Notice - Peter Campbell
12-Nov-2012
Change of Director's Interest Notice - Peter Farrell
12-Nov-2012
Change of Director's Interest Notice - Michael Quinn
12-Nov-2012
Change of Director's Interest Notice - Gary Pace
7-Nov-2012
Results of 2012 Annual General Meeting
7-Nov-2012
Chairman and Managing Director Addresses to Shareholders
26-Oct-2012
Appendix 4C - Quarter Ended 30 September 2012
10-Oct-2012
Strategic Collaboration with Paladin Labs
5-Oct-2012
Notice of 2012 Annual General Meeting and Proxy Form
24-Sep-2012
Change in substantial holding
21-Sep-2012
Annual Report to Shareholders - 2012
13-Sep-2012
2012 Annual General Meeting - Wednesday, 7 November 2012
6-Sep-2012
Investor Presentation Update - September 2012
3-Sep-2012
Independent Audit Report - 30 June 2012
30-Aug-2012
ASX/ Media Release - Preliminary Final Report 30 June 2012
30-Aug-2012
Preliminary Final Report - 30 June 2012
21-Aug-2012
CEO discusses Productive Meeting with FDA regarding MOXDUO
20-Aug-2012
Productive Meeting With FDA Regarding MOXDUO NDA
24-Jul-2012
Appendix 4C - Quarter Ended 30 June 2012
11-Jul-2012
Change in substantial holding
29-Jun-2012
Ceasing to be a substantial holder from BTT
29-Jun-2012
Ceasing to be a substantial holder from WBC
27-Jun-2012
CEO discusses Complete Response Letter from FDA
27-Jun-2012
Complete Response Letter from FDA regarding MOXDUO NDA
25-Jun-2012
Trading Halt
4-Jun-2012
Ceasing to be a substantial holder
23-May-2012
QRxPharma Granted Additional US Patent on MoxDuo
21-May-2012
Appendix 3B - Exercise of Stock Options
26-Apr-2012
US Commercialisation Partner Actavis to be acquired byWatson
17-Apr-2012
Appendix 3B - Exercise of Stock Options
17-Apr-2012
Appendix 3B - Option Issue
16-Apr-2012
Appendix 4C - Quarter Ended 31 March 2012
11-Apr-2012
Successful Completion of Phase 1 Studies for MoxDuo CR
27-Mar-2012
Appendix 3B - Exercise of Stock Options
19-Mar-2012
QRxPharma Signs License and Option Agreement with Actavis
6-Mar-2012
Investor Presentation Update - March 2012
2-Mar-2012
QRxPharma Presents at Cowen Health Care Live Audio Webcast
1-Mar-2012
Appendix 3B - Exercise of Stock Options
24-Feb-2012
Half Yearly Report and Accounts - 31 December 2011
14-Feb-2012
Dr. Edward Rudnic Joins QRxPharma as Chief Operating Officer
7-Feb-2012
Appendix 3B - Exercise of Stock Options
30-Jan-2012
Appendix 4C - Quarter Ended 31 December 2011
27-Jan-2012
Appendix 3B - Option Issue
27-Jan-2012
Appendix 3B - Exercise of Stock Options
23-Jan-2012
Change in substantial holding
23-Jan-2012
Change in substantial holding
23-Jan-2012
Change in substantial holding
23-Jan-2012
Change in substantial holding
10-Jan-2012
Investor Presentation Update - January 2012
30-Dec-2011
Change of Director's Interest Notice - John Holaday
28-Dec-2011
Change in substantial holding from BTT
28-Dec-2011
Change of Interest from WBC
22-Dec-2011
Appendix 3B - Exercise of Stock Options
21-Dec-2011
QRxPharma CEO discusses Strategic Partnership with Actavis
21-Dec-2011
QRxPharma Announces Strategic Partnership with Actavis
20-Dec-2011
Trading Halt Request
20-Dec-2011
Trading Halt
29-Nov-2011
Change in substantial holding x 4
22-Nov-2011
Change of Director's Interest Notice - John Holaday
18-Nov-2011
Appendix 3B - Option Issue
16-Nov-2011
Results of 2011 Annual General Meeting
16-Nov-2011
Chairman's and Managing Director's Addresses to Shareholders
8-Nov-2011
PDUFA Target Date for FDA Action on MoxDuo IR NDA Granted
4-Nov-2011
Appendix 3B - Exercise of Stock Options
27-Oct-2011
Appendix 4C - Quarter Ended 30 September 2011
17-Oct-2011
Appendix 3B - Option Issue
14-Oct-2011
2011 Notice of Annual General Meeting and Proxy Form
28-Sep-2011
Appendix 3B - Exercise of Stock Options
27-Sep-2011
Annual Report to Shareholders - 2011
20-Sep-2011
Change in substantial holding
7-Sep-2011
Becoming a substantial holder
1-Sep-2011
Change of Director's Interest Notice - Peter Farrell
1-Sep-2011
Change of Director's Interest Notice - Gary Pace
1-Sep-2011
Change of Director's Interest Notice - Michael Quinn
1-Sep-2011
Change of Director's Interest Notice - Peter Campbell
30-Aug-2011
Appendix 3B - Rights Issue
30-Aug-2011
Non-renounceable Rights Issue Despatch of Holding Statements
25-Aug-2011
QRxPharma Completes NDA Submission for MoxDuo IR
25-Aug-2011
Non-renounceable Rights Issue Notice of under subscriptions
18-Aug-2011
ASX/ Media Release - Preliminary Final Report 30 June 2011
18-Aug-2011
Preliminary Final Report - 30 June 2011
15-Aug-2011
Corporate Update and Rights Issue closing 22 August 2011
12-Aug-2011
Change of Director's Interest Notice - Michael Quinn
10-Aug-2011
Correction Web Address - CEO discussion on Boardroom Radio
10-Aug-2011
CEO on Recent Milestones and Rights Issue - Boardroom Radio
8-Aug-2011
Notice of Despatch of Rights Issue Documents to Shareholders
8-Aug-2011
Rights Issue - Notice to Ineligible Shareholders
8-Aug-2011
Rights Issue - Letter to U.S. Eligible Shareholders
2-Aug-2011
Appendix 3B - Exercise of Stock Options
28-Jul-2011
Appendix 4C - Quarter Ended 30 June 2011
27-Jul-2011
Notification Section 708A(5)(e) Corporations Act
22-Jul-2011
QRxPharma Rights Issue - Entitlement and Acceptance Form
22-Jul-2011
Non-Renounceable Rights Issue - Letter to Shareholders
22-Jul-2011
Non-Renounceable Rights Issue - Letter to Option Holders
22-Jul-2011
QRxPharma Rights Issue Booklet
22-Jul-2011
Notification Section 708AA(2)(f) Corporations Act
22-Jul-2011
Appendix 3B - Placement and Rights Issue
22-Jul-2011
QRxPharma Announces A$35 Million Capital Raising
20-Jul-2011
Investor Update and Capital Raising - 20 July 2011
20-Jul-2011
Trading Halt
18-Jul-2011
QRxPharma Announces NDA Filing for MoxDuo IR
13-Jul-2011
Appendix 3B - Option Issue
29-Jun-2011
Additional Data on MoxDuo IR Comparative Safety Study
20-Jun-2011
Investor Presentation Update - June 2011
15-Jun-2011
CEO discusses Comparative Safety Study on Boardroom Radio
14-Jun-2011
Successful Completion MoxDuo IR Comparative Safety Study
17-May-2011
Presentation of Clinical Data on MoxDuoTrials at APS Meeting
13-May-2011
Appendix 3B - Exercise of Stock Options
28-Apr-2011
Appendix 4C - Quarterly Report 31 March 2011
27-Apr-2011
Enrolment of MoxDuo IR Comparative Safety Study Completed
14-Apr-2011
USPTO Issues QRxPharma a New Patent for MoxDuo IR
8-Apr-2011
Change in substantial holding
7-Apr-2011
Change in substantial holding
28-Mar-2011
QRxPharma on Track to File New Drug Application Mid-Year
16-Mar-2011
Ceasing to be a substantial holder
21-Feb-2011
Half Yearly Report and Accounts -31 December 2010
21-Feb-2011
Investor Presentation Update - February 2011
21-Feb-2011
Successful Completion Third Pivotal MoxDuo IR Phase 3
27-Jan-2011
Appendix 4C - 31 December 2010
24-Jan-2011
Initiation of Phase 3 Comparative Safety Study of MoxDuo IR
6-Jan-2011
Appendix 3B - Option Issue
31-Dec-2010
QRxPharma Securities Trading Policy
6-Dec-2010
Enrolment of Pivotal MoxDuo IR Phase 3 Study Completed
26-Nov-2010
Change of Director's Interest Notice - Peter Campbell
26-Nov-2010
Change of Director's Interest Notice - Michael Quinn
19-Nov-2010
Appendix 3B - Share Purchase Plan
19-Nov-2010
$5.8 million SPP completes capital raising of $19.8 million
15-Nov-2010
Change of Director's Interest Notice - Michael Quinn
15-Nov-2010
Change of Director's Interest Notice - Gary Pace
15-Nov-2010
Change of Director's Interest Notice - Peter Campbell
15-Nov-2010
Change of Director's Interest Notice - John Holaday
15-Nov-2010
Change of Director's Interest Notice - Peter Farrell
12-Nov-2010
Change in substantial holding
9-Nov-2010
Appendix 3B - Option Issue
9-Nov-2010
Notification Section 708A(5)(e) Corporations Act 2001 (Cth)
9-Nov-2010
Appendix 3B - 2nd Tranche of Placement Issue
8-Nov-2010
Amended Company Constitution 8 November 2010
8-Nov-2010
Results of 2010 Annual General Meeting
8-Nov-2010
Chairman's and Managing Directors' Addresses to Shareholders
8-Nov-2010
Additional U.S.Therapeutic Discovery Project Grant Awarded
4-Nov-2010
Appendix 3B - Exercise of Stock Options
4-Nov-2010
MoxDuo Awarded U.S. Therapeutic Discovery Project Grants
27-Oct-2010
Appendix 3B - Option Issue
27-Oct-2010
Appendix 4C -30 September 2010
15-Oct-2010
Becoming a substantial holder
15-Oct-2010
Share Purchase Plan_Opens 18 October 2010
8-Oct-2010
2010 Annual Report to Shareholders - Printed and Web Copy
8-Oct-2010
Notice of Annual General Meeting/Proxy Form
7-Oct-2010
Notification Section 708A(5)(e) Corporations Act 2001 (Cth)
7-Oct-2010
Appendix 3B - Placement Issue announced 1 October 2010
6-Oct-2010
Appendix 3B - Option Issue
1-Oct-2010
Placement and Share Purchase Plan Listing Rule 3.10.3 Notice
1-Oct-2010
A$14 Million Placement together with a Share Purchase Plan
29-Sep-2010
Investor Update and Capital Raising - 29 September 2010
29-Sep-2010
Annual Report to shareholders - 2010
29-Sep-2010
Trading Halt
21-Sep-2010
Appendix 3B - Option Issue
1-Sep-2010
Interim Analysis of Final Pivotal Phase 3 Study MoxDuoIR
26-Aug-2010
ASX/ Media Release - Preliminary Final Report 30 June 2010
26-Aug-2010
Preliminary Final Report - 30 June 2010
18-Aug-2010
MoxDuo IR recognised for innovation in pain therapy
9-Aug-2010
Positive Phase 2 Proof of Concept Data for MoxDuoIV
26-Jul-2010
Investor Presentation Update July 2010
26-Jul-2010
Positive Scientific Advice Meetings in Europe MoxDou IR
26-Jul-2010
Appendix 4C - 30 June 2010
7-Jul-2010
Appendix 3B - Option Issue
21-Jun-2010
Appendix 3B- - Exercise of Stock Options
3-Jun-2010
Appendix 3B - Exercise of Stock Options
28-May-2010
Ceasing to be a substantial holder
10-May-2010
Phase 1 PK Study for MoxDuoCR Tablet Formula Successful
6-May-2010
Response to ASX Query - Appendix 4C
4-May-2010
Investor Presentation Update May 2010
4-May-2010
Phase 3 Combination Rule Study for MoxDuo IR Additional Data
27-Apr-2010
Appendix 4C - Quarterly Report 31 March 2010
23-Apr-2010
Appendix 3B - Exercise of Stock Options
14-Apr-2010
Phase 3 Combination Rule Study for MoxDuoIR Successful
9-Apr-2010
Becoming a substantial holder
9-Apr-2010
Ceasing to be a substantial holder
1-Apr-2010
Appendix 3B - Exercise of Stock Options
1-Apr-2010
Appendix 3B - Option Issue
30-Mar-2010
Phase 1 Trial of Controlled-Release Dual-Opioid Initiated
18-Mar-2010
Appendix 3B - Exercise of Stock Options
10-Mar-2010
Change in substantial holding
25-Feb-2010
Appendix 3B - Exercise of Stock Options
23-Feb-2010
Strategic Alliance for Development of MoxDuo IV
22-Feb-2010
Appendix 3B - Option Issue
17-Feb-2010
Half Yearly Report and Accounts - 31 December 2009
10-Feb-2010
QRxPharma Initiates Second Pivotal Phase 3 Study MoxDuoIR
27-Jan-2010
Appendix 4C - Quarterly Report 31 December 2009
18-Jan-2010
Change in substantial holding - John Holaday
18-Jan-2010
Becoming a substantial holder - John Holaday
11-Jan-2010
Appendix 3B - Option Issue
6-Jan-2010
Becoming a substantial holder
30-Dec-2009
Change in substantial holding from BTT
30-Dec-2009
Change in substantial holding from WBC
23-Dec-2009
Change of Director's Interest Notice - Gary Pace
23-Dec-2009
Change of Director's Interest Notice - John Holaday
23-Dec-2009
Change of Director's Interest Notice - Michael Quinn
23-Dec-2009
Change of Director's Interest Notice - Peter Farrell
23-Dec-2009
Change of Director's Interest Notice - Peter Campbell
23-Dec-2009
Appendix 3B - Rights Issue
23-Dec-2009
Change in substantial holding
21-Dec-2009
Rights Issue - Notice of Despatch of Shareholder Statements
18-Dec-2009
Appendix 3B - Rights Issue
18-Dec-2009
Notice of Subscriptions under Rights Issue
18-Dec-2009
Change of Director's Interest Notice - Michael Quinn
11-Dec-2009
Change of Director's Interest Notice - Michael Quinn
10-Dec-2009
Change of Director's Interest Notice - Gary Pace
10-Dec-2009
Change of Director's Interest Notice - John Holaday
10-Dec-2009
Corporate Update and Rights Issue closing 15 December 2009
30-Nov-2009
QRxPharma Initiates Pivotal Phase 3 Study of MoxDuoIR
30-Nov-2009
Notice of Despatch of Rights Issue Documents to Shareholders
30-Nov-2009
Rights Issue - Notice to Ineligible Shareholders
30-Nov-2009
Rights Issue - Letter to U.S. Eligible Shareholders
23-Nov-2009
Change of Director's Interest Notice - John Holaday
23-Nov-2009
Appendix 3B - Option Issue
20-Nov-2009
Becoming a substantial holder
19-Nov-2009
Appendix 3B - Placement Issue announced on 16 November 2009
16-Nov-2009
Results of 2009 Annual General Meeting
16-Nov-2009
Chairman's and Managing Directors' Addresses to Shareholders
16-Nov-2009
Reinstatement to Official Quotation
16-Nov-2009
Renounceable Rights Issue - Letter to Shareholders
16-Nov-2009
Renounceable Rights Issue - Letter to Option holders
16-Nov-2009
Appendix 3B - Placement and Rights Issue
16-Nov-2009
Notification Section 708AA(2)(f) Corporations Act 2001 (Cth)
16-Nov-2009
Renounceable Rights Issue - Entitlement and Acceptance Form
16-Nov-2009
QRxPharma Renounceable Rights Issue Booklet
16-Nov-2009
A$21.6 Million Fully Underwritten Placement and Rights Issue
13-Nov-2009
Investor Update and Capital Raising 13 November 2009
13-Nov-2009
Suspension from Official Quotation
11-Nov-2009
QRxPharma Investor Update and Capital Raising
11-Nov-2009
Trading Halt
26-Oct-2009
Appendix 4C - Quarterly Report 30 September 2009
20-Oct-2009
Completion of Strategic Alliance Deal for Venomics Assets
12-Oct-2009
Deal inked with Patheon for the Manufacture of MoxDou CR
12-Oct-2009
Notice of Annual General Meeting/Proxy Form
6-Oct-2009
Appendix 3B - Option Issue
29-Sep-2009
Ceasing to be a substantial holder
28-Sep-2009
Annual Report to Shareholders - 2009
28-Sep-2009
Change in substantial holding
25-Sep-2009
Change in substantial holding
24-Sep-2009
Strategic Alliance for the Development of Venomics Assets
31-Aug-2009
Appendix 3B - Option Issues
26-Aug-2009
Corporate Presentation Update August 2009
25-Aug-2009
MoxDuoIR Demonstrates Fewer Side Effects than Percocet
21-Aug-2009
ASX/ Media Release - Preliminary Final Report 30 June 2009
21-Aug-2009
Preliminary Final Report - 30 June 2009
29-Jul-2009
Response to ASX Query - Change of Director's Interest
28-Jul-2009
Appendix 4C - Quarterly Report 30 June 2009
23-Jul-2009
QRxPharma Initiates Comparative Phase 2 Sudy for MoxDuo IV
20-Jul-2009
Change of Director's Interest Notice - Michael Quinn
25-May-2009
Appendix 3B - Release of Shares from ASX Restriction
11-May-2009
Release of Shares from Voluntary Escrow and ASX Restriction
29-Apr-2009
Corporate Presentation Update April 2009
27-Apr-2009
Appendix 4C - Quarterly Report 31 March 2009
20-Apr-2009
Successful Completion of Comparative Study for MoxDuoIR
9-Mar-2009
Appendix 3B - Option Issues
9-Mar-2009
Change of Director's Interest Notice - Peter Farrell
23-Feb-2009
Half Yearly Report and Accounts 31 December 2008
19-Feb-2009
QRxPharma Initiates Second Comparative Study for MoxDuo IR
29-Jan-2009
Change in substantial holding
28-Jan-2009
Appendix 4C - Quarterly Report December 2008
22-Jan-2009
Dr Jesus Soriano as Executive Vice President
16-Dec-2008
QRxPharma Initiates Comparative Study for MoxDuoIR
10-Dec-2008
Change in substantial holding
9-Dec-2008
Becoming a substantial holder
4-Nov-2008
Chairman's and CEO's Address to Shareholders
4-Nov-2008
Results of 2008 Annual General Meeting
24-Oct-2008
Appendix 4C - Quarter Ended 30 September 2008
26-Sep-2008
Annual Report to Shareholders - 2008
26-Sep-2008
Notice of Annual General Meeting/Proxy Form
21-Aug-2008
ASX/ Media Release - Preliminary Final Report 30 June 2008
21-Aug-2008
Preliminary Final Report - 30 June 2008
12-Aug-2008
Change of Director's Interest Notice - Peter Farrell
5-Aug-2008
FDA Accepts Streamlined Phase 3 Development Plan Q8003IR
30-Jul-2008
Appendix 4C - 30 June 2008
3-Jul-2008
Change of Director's Interest Notice - Michael Quinn
1-Jul-2008
QRxPharma Begins Trading on the International OTCQX
1-Jul-2008
Change of Director's Interest Notice - Peter Campbell
30-Jun-2008
Change of Director's Interest Notice - John Holaday
27-Jun-2008
Change of Director's Interest Notice - Peter Farrell
3-Jun-2008
QRxPharma Corporate Presentation - June 2008
3-Jun-2008
QRxPharma Launches ADR Program
22-May-2008
Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
19-May-2008
Appendix 3B - Release of Shares from Restriction and Escrow
5-May-2008
Initial Phase 3 Study Results Dual Opioid Pain Therapy
5-May-2008
Corporate Presentation Update May 2008
28-Apr-2008
Appendix 4C - quarterly
1-Apr-2008
Appendix 3B - Option Issues
26-Feb-2008
Half Yearly Report and Accounts
15-Feb-2008
Company Secretary Appointment/Resignation
29-Jan-2008
Appendix 4C - Quarterly 31 December 2007
7-Jan-2008
QRxPharma Reports Feedback from the FDA - Q8003IR
4-Jan-2008
Change of Director's Interest Notice - Gary Pace
28-Dec-2007
Change of Director's Interest Notice - Gary Pace
20-Dec-2007
Ceasing to be a substantial holder
13-Dec-2007
QRxPharma Initiates Second Phase III Clinical Trial
6-Dec-2007
Change of Director's Interest Notice - Micahel Quinn
6-Dec-2007
Change of Director's Interest Notice - Michael Quinn
30-Nov-2007
Change of Director's Interest Notice - Peter Farrell
30-Nov-2007
Details of Company Address
30-Nov-2007
Quotation of Securities
26-Nov-2007
QRxPharma Enrolls First Patients in Phase III Clinical Trial
15-Nov-2007
Change of Director's Interest Notice - John Holaday
2-Nov-2007
Results of Meeting
2-Nov-2007
Chairman's Address to Shareholders
29-Oct-2007
QRxPharma Limited - Investor Update October 2007
25-Oct-2007
Change in substantial holding from WBC
22-Oct-2007
Appendix 4C - quarterly
27-Sep-2007
Annual Report to shareholders
27-Sep-2007
Notice of Annual General Meeting/Proxy Form
15-Aug-2007
Company Presentation Preliminary Final Report
15-Aug-2007
ASX/ Media Release - Preliminary Final Report
15-Aug-2007
Preliminary Final Report
7-Aug-2007
Becoming a substantial holder from WBC
3-Aug-2007
Ceasing to be a substantial holder from WBC
2-Aug-2007
Initial Substantial Shareholder Notice from WBC
27-Jul-2007
Appendix 4C - quarterly
19-Jun-2007
Release of Shares from Escrow
14-Jun-2007
Change of Director's Interest Notice
12-Jun-2007
Becoming a substantial holder
31-May-2007
Change of Director's Interest Notice
31-May-2007
Change of Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
31-May-2007
Initial Director's Interest Notice
25-May-2007
QRxPharma Limited completes IPO/Trading commences on ASX
25-May-2007
Pre-Quotation Disclosure
25-May-2007
Top 20 shareholders
25-May-2007
Distribution Schedule
25-May-2007
Admission to Official List
24-May-2007
ASX Circular: Commencement of Official Quotation
24-May-2007
Constitution
24-May-2007
Pre-quotation Disclosure re Shares and Options
24-May-2007
Financial Statements 31 December 2006
24-May-2007
Financial Statements 30 June 2006
24-May-2007
Financial Statements 30 June 2005
24-May-2007
Financial Statements 30 June 2004
23-May-2007
Corporate Governance Statement
23-May-2007
Full terms & conditions of ESOP
21-May-2007
Appendix 1A: ASX Listing application and agreement
16-May-2007
Disclosure Document